Aspire Biopharma Holdings (ASBP) Current Assets (2021 - 2026)
Aspire Biopharma Holdings (ASBP) posted quarterly Current Assets of $7.1 million for Q1 2026, up 262.1% year-over-year from $2.0 million in Q1 2025, and up 442.4% quarter-over-quarter from $1.3 million in Q4 2025.
Aspire Biopharma Holdings (ASBP) Current Assets (2021 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Current Assets for 6 consecutive years, with $7.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets rose 262.1% year-over-year to $7.1 million; the TTM figure through Mar 2026 stood at $7.1 million (up 262.1% YoY), while the FY2025 annual figure was $1.3 million, up 786.66% from the prior year.
- Current Assets grew to $7.1 million in Q1 2026 per ASBP's latest filing, from $1.3 million in the prior quarter.
- Across five years, Current Assets topped out at $7.1 million in Q1 2026 and bottomed at $65577.0 in Q1 2024.
- Historically, Current Assets has averaged $1.3 million across 5 years, with a median of $1.0 million in 2022.
- Annual changes were most pronounced in 2024 — Current Assets tumbled 92.77% — and 2025, when it jumped 2897.26%.
- Aspire Biopharma Holdings' Current Assets stood at $1.1 million in 2022, then tumbled by 92.6% to $81223.0 in 2023, then surged by 82.2% to $147989.0 in 2024, then surged by 786.66% to $1.3 million in 2025, then surged by 442.4% to $7.1 million in 2026.
- Business Quant data shows ASBP's Current Assets at $7.1 million in Q1 2026, $1.3 million in Q4 2025, and $2.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.76 Bn |
| 10 | Aspire Biopharma Holdings | 8.30 Mn | -3.86 Mn | -30,086.00 | 13.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.47 Mn |
| Mar 31, 2026 | 7.12 Mn |
| Dec 31, 2025 | 1.31 Mn |
| Sep 30, 2025 | 2.40 Mn |
| Jun 30, 2025 | 989,422.00 |
| Mar 31, 2025 | 1.97 Mn |
| Dec 31, 2024 | 147,989.00 |
| Jun 30, 2024 | 342,973.00 |
| Mar 31, 2024 | 65,577.00 |
| Dec 31, 2023 | 81,223.00 |
| Sep 30, 2023 | 253,362.00 |
| Jun 30, 2023 | 546,144.00 |
| Mar 31, 2023 | 906,455.00 |
| Dec 31, 2022 | 1.10 Mn |
| Sep 30, 2022 | 1.15 Mn |
| Jun 30, 2022 | 1.21 Mn |
| Mar 31, 2022 | 1.26 Mn |
| Dec 31, 2021 | 293,221.00 |